Opinion|Videos|June 24, 2024
Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER
The panelists examine the latest findings from the CheckMate 214 trial, which assessed the combination of nivolumab and ipilimumab (nivo + ipi) as a first-line treatment for advanced renal cell carcinoma, focusing on efficacy, safety, and quality of life outcomes.
Advertisement
Episodes in this series
- Please briefly discuss the recent data from the CheckMate 214 trial evaluating nivo + ipi for 1L treatment of advanced RCC.
- 8-year follow-up and subgroup analyses – please comment on OS, DOR, PFS, TFS, and safety (
Tannir et al., ASCO GU 2024 Abstract 363 ) - What insights do the recent HRQoL data provide? (
Cella et al., Oncologist Jan 2024 )
- 8-year follow-up and subgroup analyses – please comment on OS, DOR, PFS, TFS, and safety (
- Please comment on the role of doublet regimens in the 1L setting for advanced RCC and their recent data updates.
- CheckMate 9ER nivo + cabo
- 55-month follow up (
Bourlon et al., ASCO GU 2024 Abstract 362) - HRQoL (
Bedke et al., ASCO GU 2024 Abstract 384 ) - Partitioned 4-year OS (
Mantia et al., ASCO 2024 Abstract 4507 )
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.
In a phase 1/2 study, the LSD1 inhibitor bomedemstat reduced spleen volume, improved symptoms, and lowered driver mutation burden in patients with advanced myelofibrosis.
Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.
The NMPA accepted the NDA for the PD-L1/4-1BB–directed bispecific antibody opamtistomig in previously treated advanced extrapulmonary NEC.
Obesity can weaken the immune system and lead to disease progression, but Roswell Park experts revealed that exercise may reverse that effect.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
The OncFive: Top Oncology Articles for the Week of 8/16
4
Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC
5